JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

CTHRC1 expresses in cancer-associated fibroblasts and is associated with resistance to anti-androgen therapy in prostate cancer

  • 0Department of Urology, The First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Nanning, 530021, China.
Genes & Genomics +

|

February 26, 2025

|

February 26, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

High CTHRC1 expression in prostate cancer correlates with poorer prognosis and resistance to anti-androgen therapy (ADT). Targeting CTHRC1 may offer new diagnostic and therapeutic strategies for prostate cancer treatment.

Area Of Science

  • Oncology
  • Molecular Biology
  • Genomics

Background

  • CTHRC1 is overexpressed in prostate cancer, promoting cell proliferation, invasion, and migration.
  • The precise role of CTHRC1 in prostate cancer prognosis and treatment outcomes is not well understood.

Purpose Of The Study

  • To investigate the expression patterns of CTHRC1 in prostate cancer.
  • To elucidate the functional significance of CTHRC1 in prostate cancer progression.
  • To evaluate the prognostic value and therapeutic implications of CTHRC1.

Main Methods

  • Utilized bulk and single-cell RNA sequencing on 1999 prostate cancer cases and 531 controls.
  • Analyzed CTHRC1 expression, prognostic correlations, and immune cell infiltration using CIBERSORT.
  • Predicted drug sensitivity to anti-androgen therapy (ADT) using the GDSC database.

Main Results

  • CTHRC1 expression is elevated in prostate cancer and increases with disease progression.
  • Higher CTHRC1 levels are associated with a worse progression-free interval (PFI) and increased tumor-associated macrophage (TAM) infiltration.
  • CTHRC1-positive myofibroblast-like cancer-associated fibroblasts (myCAFs) activate TGF-β signaling and are linked to ADT resistance, potentially via the CCN2/CAV1/AR pathway.

Conclusions

  • CTHRC1 is a significant risk factor for prostate cancer progression.
  • CTHRC1 expression in myCAFs influences the tumor microenvironment and hormone response.
  • CTHRC1 represents a potential therapeutic target for overcoming ADT resistance in prostate cancer.

Keywords:

Related Concept Videos

mTOR Signaling and Cancer Progression 03:03

3.7K

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Abnormal Proliferation 02:23

4.4K

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

Mitogens and the Cell Cycle 02:38

6.4K

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Treatment Resistant Cancers 02:56

3.2K

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

The Tumor Microenvironment 02:17

6.5K

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...